Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 2650 of 2873 entries
View as:

Ofatumumab for Minimal Residual Disease (MRD) and Maintenance Therapy

Phase: N/A Priority: Normal
NCT ID: NCT01258933 Org: User:
Start: 07/06/11 End: 10/18/24 Due: 10/18/25

PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

Phase: N/A Priority: Normal
NCT ID: NCT04022785 Org: User:
Start: 09/09/19 End: 10/24/22 Due: 10/24/23

Fentanyl Buccal Tablet or Morphine for Exertional Dyspnea in Cancer Patients

Phase: N/A Priority: Normal
NCT ID: NCT04188418 Org: User:
Start: 10/23/20 End: 08/31/25 Due: 08/31/26

Study of ABT-751 in Patients With Refractory Hematologic Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT00047489 Org: User:
Start: 12/31/02 End: 01/31/05 Due: 01/31/06

Spirituality/Religiosity in Patients and Caregivers

Phase: N/A Priority: Normal
NCT ID: NCT00634257 Org: User:
Start: 02/22/08 End: 02/10/22 Due: 02/10/23

Autologous Cytomegalovirus (CMV)-Specific Cytotoxic T Cells for Cytomegalovirus (CMV) Reactivation

Phase: N/A Priority: Normal
NCT ID: NCT02210065 Org: User:
Start: 03/03/15 End: 05/13/19 Due: 05/13/20

The Effects of Ginseng on Cancer-Related Fatigue

Phase: N/A Priority: Normal
NCT ID: NCT01375114 Org: User:
Start: 10/14/11 End: 10/31/25 Due: 10/31/26

Neoadjuvant Ifosfamide, Doxorubicin, Gemcitabine, and Cisplatin in Treating Patients Who Are Undergoing Radical Cystectomy for Locally Advanced Carcinoma (Cancer) of the Urothelium

Phase: N/A Priority: Normal
NCT ID: NCT00080795 Org: User:
Start: 07/31/01 End: 05/31/06 Due: 05/31/07

A Study for Reducing Symptom Burden Produced by Chemoradiation Treatment for Non Small Cell Lung Cancer by Minocycline and Armodafinil

Phase: N/A Priority: Normal
NCT ID: NCT01317550 Org: User:
Start: 07/31/11 End: 02/29/16 Due: 02/28/17

Three-Factor Eating Questionnaire in Measuring Eating Behavior in Adolescent and Young Adult Survivors of CNS Tumors

Phase: N/A Priority: Normal
NCT ID: NCT01682824 Org: User:
Start: 05/17/13 End: 01/24/22 Due: 01/24/23

Nivolumab in Treating Patients With Primary Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis, or Post-Polycythemia Vera Myelofibrosis

Phase: N/A Priority: Normal
NCT ID: NCT02421354 Org: User:
Start: 05/14/15 End: 04/13/18 Due: 04/13/19

Dexamethasone Dyspnea Study

Phase: N/A Priority: Normal
NCT ID: NCT01670097 Org: User:
Start: 01/31/13 End: 01/26/21 Due: 01/26/22

Physical Activity in Promoting Smoking Cessation in African Americans

Phase: N/A Priority: Normal
NCT ID: NCT01915810 Org: User:
Start: 01/29/14 End: 01/31/27 Due: 01/31/28

Study of Weekly Clofarabine for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT00081887 Org: User:
Start: 05/31/04 End: 06/30/07 Due: 06/30/08

Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT05032183 Org: User:
Start: 02/17/22 End: 07/31/24 Due: 07/31/25

Predictive Biomarkers for Pneumonitis After Chemoradiotherapy and Immunotherapy in Patients With Non-small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04913311 Org: User:
Start: 01/21/21 End: 02/02/27 Due: 02/02/28

Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before Surgery

Phase: N/A Priority: Normal
NCT ID: NCT02812420 Org: User:
Start: 03/07/17 End: 12/31/27 Due: 12/31/28

Trial of ID-Specific Donor Vaccinated Lymphocyte Infusion for Patients With Myeloma Relapsing or Failing to Achieve a Complete Remission After an Allogenic Transplant

Phase: N/A Priority: Normal
NCT ID: NCT01174082 Org: User:
Start: 07/20/10 End: 02/23/17 Due: 02/23/18

Injection Methods in Finding the Sentinel Lymph Node During Lymphatic Mapping and Sentinel Lymph Node Biopsy in Patients With Invasive Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00438477 Org: User:
Start: 06/30/05 End: 04/30/08 Due: 04/30/09

Vemurafenib, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery

Phase: N/A Priority: Normal
NCT ID: NCT01787500 Org: User:
Start: 02/15/13 End: 03/31/26 Due: 03/31/27

Fostamatinib for the Treatment of Lower-risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia Who Have Failed Therapy With Hypomethylating Agents

Phase: N/A Priority: Normal
NCT ID: NCT05030675 Org: User:
Start: 08/13/21 End: 08/08/24 Due: 08/08/25

Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic

Phase: N/A Priority: Normal
NCT ID: NCT02721732 Org: User:
Start: 08/15/16 End: 12/31/25 Due: 12/31/26

Parent and Family Obesity Intervention in Reducing Obesity Risk in Racial Ethnic Minority Families

Phase: N/A Priority: Normal
NCT ID: NCT05094466 Org: User:
Start: 07/16/19 End: 02/02/27 Due: 02/02/28

The Use of Cytomegalovirus Cell Mediated Immunity to Optimize the Duration of Letermovir Prophylaxis in Hematopoietic Cell Transplant Recipients

Phase: N/A Priority: Normal
NCT ID: NCT06639854 Org: User:
Start: 11/20/24 End: 12/31/26 Due: 12/31/27

Effect of Pulmonary Rehabilitation on Surgical Outcomes in the Cancer Setting

Phase: N/A Priority: Normal
NCT ID: NCT00618553 Org: User:
Start: 01/28/08 End: 09/01/25 Due: 09/01/26